I disagree with you. Firstly I have no idea about what you mean 'positive', 80% accuracy or 90%? Secondly, commercialisation does not require FDA approval. The tool can be a supplementary diagnostic tool used to facilitate the formal diagnostic process. Although the sale price will be much lower (e.g. $1-2 per test instead of suggested $5-10) due to less certified, they can still generate revenue if with good marketing strategy. Of course, with FDA approval, the market scale and profit will be another story.
- Forums
- ASX - By Stock
- Ann: Notice of Acceptance Received for Core Patent in Australia
I disagree with you. Firstly I have no idea about what you mean...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online